Venue | Press Room | Subscribe | Site Map
TechConnect Summit 2006
Home | About the Summit | Program | Advisory Boards | About TechConnect

Producing Sponsor

TechConnect

Platinum Sponsor

Welsh & Katz, Ltd.

Gold Sponsor

ISTC International Science & Technology Center

Ventures Enabling Sponsor

Atomic Venture Partners

Press Sponsor

Business Wire

Partnering Sponsor

NSTI

Supporting Organizations

Boston University
Midwest Research University Network

Media Sponsors

(joint with Nanotech 2006) Nature
Science
R&D Magazine

Summit News

Event Contact

Jennifer Rocha
955 Massachusetts Ave. #313
Cambridge, MA 02139
Phone: (774) 249-8514

Copper-Dependent Non-Traditional Pro-Inflammatory Cytokine Export and Methods

Organization:Maine Medical Center Research Institute, Maine Medical Center Research Institute, US
I.P. Brief:The inventors have discovered that non-traditional export of certain pro-inflammatory cytokines lacking a signal sequence from a cell can be inhibited by copper chelation.
Summary of I.P.:Copper chelation inhibits neointima formation, macrophage infiltration and associated inflammation, cell proliferation, secretion of extracellular matrix, intimal thickening, adventitial angiogenesis, restenosis, and vascular vessel injury in general. This invention describes a unique way of managing Interleukin-1 and FGF activity at the cellular level, which leads to the opportunity for a variety of therapeutic benefit. In vivo data has been generated and is available under a confidentiality agreement. Advantages: This invention provides novel methods for preventing and treating various diseases, including Alzheimers, Lupus, and Arthritis. There is a striking similarity to the structure of FGF and therefore leads to the hypothesis that these may be treated like a vascular disease. There are complimentary patents available as well.
Patent:Patents pending
Keywords:FGF, IL-1, lupus, alzheimers, arthritis
Primary Industry:Pharma & Biotech
Specific Market:Alzheimers, Lupus, Arthritis
Market Size:In excess of $1 billion
State of the Art:There are various strategies for each indication.
Figures of Merit:This is part of a broad family of IP that can be used to address these indications.
Tech.  Obstacles:None known at this time.
Market Obstacles:Need to move from mouse models to larger animal models to validate the concept.
Publications:Tarantini, F., Micucci, I., Bellum, S., Landriscina, M., Garfinkel, S., Prudovsky, I., and T. Maciag. The Precursor But Not the Mature Form of IL1• Blocks the Release of FGF1 in Response to Heat Shock, J. Biol. Chem., Rapid Commun., 2001; 276:5147-5151. Prudovsky, I., Mandinova, A., Soldi, R., Bagalá, C., Graziani, I., Landriscina, M., Tarantini, F., Duarte, M., Bellum, S., Doherty, H. and Maciag, T. The Non-Classical Export Routes: IL1 and FGF1 Point the Way. J. Cell Sci. 2003; 118:4871-81.
Research Team:Igor Prudovsky

 

Home | About the Summit | Program | Advisory Boards | About TechConnect
Terms of use | Privacy policy | Contact | TechConnect Home
© 2005 TechConnect. All rights reserved.